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Abstract
Background: Among all the treatment methods developed 
so far, opioid agonist treatment (OAT) is the most effective 
therapy for opioid dependence. While methadone (MTD) is 
the most commonly used, fewer data are available on alter-
native opioid agonist. The aim of this study was to assess the 
efficacy of buprenorphine (BUP) and slow-released mor-
phine compared to MTD with regard to the reduction of con-
comitant heroin and cocaine use. Methods: This cross-sec-
tional study included 105 patients receiving MTD, BUP, or 
slow-release morphine as opioid agonist therapy at the Psy-
chiatric Hospital of Zurich. Illicit drug use was assessed using 
a retrospective 3-month hair toxicology analysis to quantify 
concentrations of heroin degradation products and metabo-
lites, as well as cocaine and cocaine metabolites. We have 
also collected self-reports, but in the data of the study, only 
the results of the hair analysis were considered. Results: 
BUP-treated patients showed lower rates of illicit opiate con-
sumption in comparison to the group treated with MTD or 
slow-released morphine (p < 0.05). The proportion of heroin-
positive hair samples associated with slow-release morphine 
treatment was similar to the proportion associated with MTD 
treatment. Neither the MTD vs. slow-released morphine 
groups nor the BUP vs. MTD groups showed significant dif-
ferences in the number of patients consuming cocaine al-
though patients in the BUP group had significantly lower 
concentrations of cocaine in hair testing compared to the 
patients in the MTD group. Prevalence of cocaine consump-
tion was also significantly lower in the BUP group compared 
to patients in the slow-release morphine group (p < 0.05). 
Conclusion: This study suggests that BUP OAT is associated 
with reduced additional opiate co-use.













































































Opioid dependence is a chronic relapsing disorder with 
important public health implications, and affects about 
15.6 million patients worldwide [1]. One of the most effec-
tive therapies for opioid dependence is opioid agonist 
treatment (OAT) [1]. Together with psychological sup-
port, this treatment stabilizes opioid-dependent patients 
and reduces illicit opioid use, infectious-disease transmis-
sion, and death due to overdose [2, 3]. Some studies not 
only observed an effect of OAT on heroin use, but also 
reported on a significant reduction of concomitant co-
caine use [4, 5]. Further benefits include improved quality 
of life and improved social reintegration [6]. The most 
commonly prescribed medication in OAT Switzerland 
and Europa is methadone (MTD) [6, 7]. MTD was the first 
and is now the most established OAT medication, with its 
effectiveness proven in many studies [8]. However, there 
are patients who do not tolerate MTD or have an inade-
quate withdrawal suppression often associated with high 
illicit opioid co-consumption [9]. In addition, some spe-
cific side effects of MTD influence compliance and limit 
its clinical usefulness, such as weight gain, sweating, de-
pressive symptoms, loss of libido, QT-prolongation and a 
potential for interactions with other medications [10]. 
In Europe, other treatment options such as buprenor-
phine (BUP) and slow-release oral morphine (SROM) are 
available. BUP is a partial μ-opiate agonist and κ-opiate 
antagonist with established efficacy in the treatment of 
opiate dependence. As BUP undergoes extensive first-
pass metabolism it has to be taken sublingually [11]. BUP 
has some advantages over MTD as it is less pro-arrhyth-
mic, carries a lower risk of respiratory depression when 
overdosed, and has a longer duration of action that allows 
dispensing at intervals of 2–3 days [12]. Studies have 
shown that BUP leads to significantly lower consumption 
of illicit opioids [7, 13, 14], and also seems to reduce con-
comitant cocaine use [15]. In subjects affected by depres-
sion and mood disorders in particular, BUP reduced rates 
of illicit opiate consumption [16]. 
Morphine is a full μ-opioid receptor agonist. Once-a-
day SROM is an approved medication with proven effi-
cacy and safety for the treatment of opioid dependence 
[17, 18]. SROM may result in reduced opioid craving and 
improved tolerability compared to MTD [9, 19], and is at 
least as effective as MTD in reducing illicit opioid con-
sumption [20]. 
Familiarity with effective alternatives to MTD is not 
universal among psychiatrists, as shown in a recent study 
from Switzerland reporting that 17% of treating psychia-
trists were unaware of the existence of effective treat-
ments other than MTD [7]. It is important that psychia-
trists are aware of the existence of alternative medications 
for OAT in order to optimize and individualize therapy. 
Alternative medication may sometimes have a better ef-
fect on withdrawal symptoms, craving behaviour and the 
reduction of illicit opioid co-use. 
The aim of this study was to evaluate the effectiveness 
of MTD, BUP and SROM with regard to reduction of her-
oin and/or cocaine co-use in opioid-dependent patients 
in OAT. We hypothesized that BUP and slow-release 
morphine would be as effective or superior to MTD main-
tenance treatment in terms of the outcome measures il-
licit opioid and cocaine use.
Materials and Methods
Subjects
The study was conducted in 2014 in an outpatient setting at the 
Centre for Addictive Disorder of the Psychiatric Hospital Zurich 
[21]. OATs in Switzerland are covered by mandatory health insur-
ance. Every patient who is diagnosed with heroin dependence is 
accepted for treatment and there is no waiting time. The choice of 
the appropriate OAT medication depends mainly upon patients 
and providers rather than regulatory constraints [22]. The treat-
ment can be provided in specialised outpatient centres or private 
practices. All patients who were in OAT at the time of study execu-
tion with either MTD, BUP or SROM were invited to participate 
in the study, and 105 patients (28 females, 77 males; mean age 
41.2 ± 8.8 years) were enrolled. The inclusion criterion for par-
ticipation was the diagnosis of opioid dependence according to the 
DSM-IV criteria. The exclusion criteria were age under 18 and 
over 65 years and insufficient German language skills. Patients 
with psychiatric comorbidities or prescribed medication other 
than opioid substation were not excluded. 
Study Design
In this cross-sectional study, all patients in OAT were recruited 
to participate in the study when they came to collect their opioid 
agonist medication. Participants were then categorized into 3 
treatment groups depending on the opioid agonist medication 
currently taken. Demographic data such as age, gender, years and 
type of education, employment status, number of clinical treat-
ments, as well as medication and self-report drug use, were as-
sessed with self-reported questionnaires. Data on psychiatric diag-
nosis at the time of study recruitment were collected from elec-
tronic medical records of the patients. Depression and anxiety 
were assessed using the Beck Depression Inventory [23] and State-
Trait Anxiety Inventory [24]. Craving was assessed with a Visual 
Analog Scale ranging from 1 to 100) [25]. 
Study Assessment
The primary outcome was the prevalence of concomitant her-
oin (6-monoacetylmorphine [MAM]) and cocaine use detected by 
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phy-tandem mass spectrometry) [26]. A secondary goal was to de-
termine the concentration of heroin and cocaine in the hair sam-
ples and to identify possible factors such as the substitution dose 
or craving behaviour. 
Hair Analysis
The measure for assessing illicit drug use was a 3-month hair 
toxicology analysis, which was carried out at the Institute of Fo-
rensic Medicine at the University of Zurich. Whenever possible 
head hair was used, but body hair was used in cases where little or 
no, or only heavily bleached hair was available. In the hair analysis, 
only the proximal 3-cm section of the collected head hair locks was 
investigated. Assuming an average growth rate of 1 cm/months, 
this hair segment represents the consumption behaviour of the last 
3–4 months before collection. The analytical limits of the method 
enable the detection of very low concentration in the hair samples. 
However, strong cosmetic treatments like bleaching can degrade 
the incorporated substances [27]. Hair was analysed according to 
Rust et al. [28]. The hair sample was washed in water, acetone and 
hexane for 2 min each. Then it was dried at room temperature, cut 
into small snippets and extracted in methanol (extraction step 1) 
and a mixture of methanol and ammonium formate buffer (extrac-
tion step 2) for 90 min each. After each extraction step, the organ-
ic layers were separated by centrifugation and dried under a stream 
of nitrogen at 36 ° C. Finally, the residues were combined, redis-
solved in methanol and aqueous ammonium format buffer solu-
tion and then the samples were analysed with LC-MS/MS. Positive 
heroin and cocaine use was confirmed by the presence of MAM or 
cocaine + cocaethylene, respectively, using cut-off values of 
15 pg/ mg MAM and 60 pg/mg cocaine + cocaethylene. These low 
threshold values discriminate between the abstinence and occa-
sional use of drugs.
Statistical Analysis
Data analysis was carried out using SPSS 24 (SPSS, Chicago, 
IL, USA). Differences in baseline characteristics between treat-
ment groups were compared by Student t tests for continuous 
variables and chi-square tests for categorical variables. In order 
to compare the 3 OAT groups for additional heroin and/or co-
caine consumption, we analysed heroin and cocaine hair concen-
trations using the Kruskal-Wallis-Test for non-parametric vari-
ables. Normal distribution was tested with Kolmogorov-Smirnov 
Test. To determine the percentage of patients with additional 
heroin or cocaine consumption, we recoded the results of the hair 
analysis, classifying all values ≥1 as yes and all values = 0 as no, 
and then compared the substitution groups using the Pearson 
chi-square test. To detect correlations between substitution dose, 
craving and drug consumption we used the two-tailed Spear-
man-Rho correlation test after conducting a log-transformation 




We recruited 110 opioid-addicted patients in opioid 
agonist therapy. Because of missing data due to incom-
plete questionnaire and medical record data, 5 patients 
had to be excluded. Many subjects had comorbidities, 
with over 80% being diagnosed with at least one other 
psychiatric disorder in addition to the opioid depen-
dence, and nearly half reporting a diagnosis of hepatitis 
C (41.2%). There were no significant differences be-
tween the 3 substitution groups in age, gender, years and 
type of education, employment status, number of clini-
cal treatments, number of psychiatric comorbidities, 
BDI score or the frequency of occurrence of HIV or 
Hepatitis C. Detailed patient characteristics are shown 
in Table 1. 
Pharmacological Treatment
The substitutes, at the appropriate dose, were pre-
scribed by doctors who were not part of the current 
study. Of the 105 participants, 69 patients received OAT 
therapy with MTD, 17 with BUP and 19 with SROM. 
The mean ± SD dose per day of MTD was 97.3 ± 67.1 mg, 
10.1 ± 8.5 mg of BUP or 515.3 ± 285.3 mg of SROM. In 
patients with a recent change in opioid agonist medica-
tion or dose, the medication at the time of recruitment 
was used, and in case of doubt, the lower dose was cho-
sen. 
Identification of Drug Consumption by Hair Analysis
The hair analysis results showed significant differenc-
es between the 3 substitution medication groups in terms 
of additional heroin and cocaine consumption. If we only 
consider the presence or absence of heroin consumption, 
heroin co-use within a 3-month period was shown by hair 
testing in 62.3% of patients in the MTD group, in 23.5% 
of the BUP group and in 63.2% of the SROM group 
(Fig.  1). Thus, significantly fewer patients in the BUP 
group showed detection of heroin consumption com-
pared to the MTD group (Pearson chi-square test, X2 
[1] = 8.281, p < 0.01) and the SROM group (Pearson chi-
square test, X2 [1] = 5.707, p < 0.05). By contrast, the MTD 
and SROM groups showed no significant differences 
(Pearson chi-square test, X2 [1] = 0.004, p = 0.947). When 
we analysed heroin hair concentrations, we found that 
patients on BUP substitution consumed significantly less 
compared to patients taking MTD as a substitute (Krus-
kal-Wallis test, X2 [1] = 5.530, p < 0.05). No other 
 significant differences were found for either the MTD vs. 
SROM groups (Kruskal-Wallis test, X2 [1] = 0.071, 
p = 0.79) or the SROM vs. BUP groups (Kruskal-Wallis 
test, X2 [1] = 3.533, p = 0.06). 
Cocaine consumption was detected in 79.7% of pa-












































































and in 84.2% of the SROM group. There were no sig-
nificant differences between the 3 groups (MTD vs. 
BUP p = 0.19, SROM vs. BUP p = 0.17, MTD vs. SROM 
p = 0.66).
However, the patients in the BUP group used 
 significantly lower doses of cocaine than the patients in 
the MTD group (Kruskal-Wallis test, X2 [1] = 5.276, p < 
0.05) and the SROM group (Kruskal-Wallis test, X2 
[1] = 4.093, p < 0.05). There was no significant differ-
ence in the cocaine concentration in the MTD vs. 
SROM groups (Kruskal-Wallis test, X2 [1] = 0.288, 
p = 0.591). 
There was a significant positive correlation between 
heroin and cocaine hair concentration (Spearman Rho 
correlation, two-tailed, r = 0.519, p < 0.01), indicating that 
high-dose users of heroin also show a high-dose use of 
cocaine. Heroin craving correlated with the MAM (hero-
in-use marker) hair concentration (Spearman Rho cor-
relation, two-tailed, r = 0.406, p < 0.01), just as cocaine 
craving correlated with cocaine hair concentration 
(Spearman Rho correlations, two-tailed, r = 0.504, 
p  < 0.01), confirming that high craving usually goes along 
with elevated drug co-consumption. In the case of BUP 
substitution, we found a significantly negative correlation 
between the dose of the medication and craving for her-
oin (Spearman Rho correlations, two-tailed, r = –0.549, 
p < 0.05), and a trend for negative correlation between the 
BUP medication dose and heroin co-consumption, 
(Spearman Rho correlations, two-tailed, r = –0.469, 
p = 0.058.










Gender, n (%) 0.2961
Male 48 (69.6) 15 (88.2) 14 (73.7) 77 (73.3)
Female 21 (30.4) 2 (11.8) 5 (26.3) 28 (26.7)
Age, years, mean ± SD 41.15±8.1 41.95±9.3 39.68±10.8 41.19±8.8 0.7142
School, n (%) 0.8261
None 2 (2.9) 0 (0) 1 (5.3) 3 (2.9)
Middle school 25 (36.2) 5 (29.4) 5 (26.3) 35 (33.3)
High school 34 (49.3) 8 (47.1) 10 (52.7) 52 (49.5)
Academic high school 8 (11.6) 4 (23.5) 3 (15.8) 15 (14.3)
Education, n (%) 0.0631
None 15 (21.7) 2 (11.8) 7 (36.8) 24 (22.9)
Apprenticeship 51 (73.9) 14 (82.4) 8 (42.1) 73 (69.5)
University of applied science 2 (2.9) 1 (5.9) 2 (10.5) 5 (4.8)
University 1 (1.4) 0 (0) 2 (10.5) 3 (2.9)
Employed, n (%) 0.1171
Full-time 3 (5.3) 3 (20.0) 1 (5.6) 7 (7.0)
Part-time 6 (9.0) 0 (0) 1 (5.6) 7 (7.0)
Unemployed 8 (11.9) 2 (13.3) 0 (0) 10 (10.0)
Disability 38 (56.7) 5 (33.3) 14 (77.8) 57 (57.0)
Student 0 (0) 1 (6.7) 0 (0) 1 (1.0)
Certified sick 3 (4.5) 1 (6.7) 1 (5.6) 5 (5.0)
Other 9 (13.4) 3 (20) 1 (5.6) 13 (13.0)
Number of psychiatric comorbidities, mean ± SD 1.62±1.1 1.18±0.9 2±1.1 1.6±1.1 0.4972
Number of clinical treatments, mean ± SD 6.68±8.2 5.15±5.3 5.96±6.7 6.3±7.5 0.7482
BDI, mean ± SD 17.09±9.1 14.12±9.2 16.68±9.1 16.51±9.1 0.5012
HIV, n (%) 0.8541
Yes 5 (7.5) 0 (0) 1 (5.3) 6 (5.9)
No 51 (76.1) 13 (81.3) 15 (78.9) 79 (77.5)
Unknown 11 (16.4) 3 (18.8) 3 (15.8) 17 (16.7)
Hepatitis C, n (%) 0.0631
Yes 28 (41.8) 3 (18.8) 11 (57.9) 42 (41.2)
No 39 (58.2) 13 (81.3) 8 (42.1) 60 (58.8)
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Discussion
The results of this study suggest that substitution with 
BUP is associated with a lower level of additional heroin 
use compared to substitution with MTD or SROM. More-
over, the BUP-treated group also consumed a lower dose 
of cocaine compared to the MTD and SROM groups. 
To the best of our knowledge, this is the first study to 
examine concomitant heroin and cocaine consumption 
in opioid-dependent patients in OAT using hair toxicol-
ogy analysis. For the detection of drug use over a longer 
period of time, hair analysis is superior to the more com-
monly-used urine analysis [29, 30]. The results of the hair 
analysis allowed us to compare, under daily practice con-
ditions, the 3 substitution medications most commonly 
used in Switzerland for their effectiveness in reducing 
long-term concomitant heroin and cocaine consump-
tion. 
In this study, we found a negative correlation between 
the dose of BUP and heroin craving and consumption. 
This indicates that the dose of BUP in opioid agonist ther-
apy should be high enough in order to receive an ade-
quate therapeutic effect. We also detected a correlation 
between heroin and cocaine consumption. McCance-
Katz et al. [31] have shown that chronic cocaine use de-
creases the BUP and MTD concentration in blood, with 
a potential reduction in response to treatment. Whether 
this effect also holds for SROM is not yet known, but this 
mechanism does represent a compelling rationale for the 
correlation between concomitant cocaine use and opioid 
agonist therapy failure in the form of increased heroin 
consumption. BUP and SROM are non-inferior to MTD 
and are suitable alternatives to MTD for the OAT of her-
oin-dependent patients if MTD is not tolerated, if there is 
inadequate withdrawal suppression or a high illicit con-
sumption of opioids. 
Certain limitations should be mentioned. Screening 
was conducted in a single centre only and included a lim-
ited number of participants. This resulted in a lack of sta-
tistical power, particular in the BUP group. The natural-
istic study design meant that all patients enrolled in this 
study were already under specific OAT and the assign-
ment to the 3 different substitution medications was not 
randomized. This raises the possibility that allocation to 
the 3 treatment groups might have resulted in selection 
bias, particularly in view of the partial self-selection of 
patients to the different types of OAT medications that is 
common in Switzerland [22]. However, no significant 
differences between the 3 substitution groups were found 
regarding demographic variables such as age, gender, 
years and type of education, employment status, number 
of clinical treatments, number of psychiatric comorbidi-
ties, BDI score, or frequency of occurrence of HIV or 
Hepatitis C. Nevertheless, certain socioeconomic differ-
ences may have been overlooked due to the small total 
number of patients. Furthermore, the cross-sectional 
study design does not allow the inference of cause-effect 
relationships. The proportion of heroin or cocaine-posi-
tive hair samples in each substitution group and the quan-
titative measurement of heroin or cocaine by hair analysis 
was selected as the most important end-point because 
concomitant drug use was expected to be more relevant 
in this cross-over study than the retention-in-treatment 
rate. The influence of the different substitution medica-
tions on the retention rate was estimated to be relatively 
modest in ongoing maintenance treatment, and other 
studies have shown no difference in the retention-in-
treatment rate, or in the case of BUP only, in the first day 
of treatment (possibly because of a too low induction 
dose) [19, 32].
This study indicates that BUP is superior to MTD 
and SROM in terms of reducing illicit opioid and co-
caine co-use. The cross-sectional character of the study 
means that no causal conclusions can be drawn and 
these findings need to be confirmed in a larger, random-
ized study. Further studies are needed to identify prog-
nostic variables that allow optimal matching of patients 
to treatments, and the field of opioid agonist therapy in 
general needs to develop further in order to allow physi-
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Fig. 1. Heroin consumption: percentage of patients with addition-
al heroin consumption within the 3 substitution groups. MTD, 














































































All participants provided written informed consent before 
admission to the study and were compensated with 5 Swiss 
Francs for their participation. The study protocol was  approved 
by the local Ethics Committee of the canton of Zurich. 
Disclosure Statement
M.H. received compensation for consultancy and a speaker’s fee 
from Lundbeck. J.M. has received travel expenses and speaker fees 
from Lundbeck, Indivior and Takeda. B.B.Q. received a speaker’s fee 
from Lundbeck. M.S. has worked as consultant and has received trav-
el or research grants from Lundbeck, Indivior and Mundipharma.
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